Get the Stockscreener App
54.15
3.85%
2.00
After Hours:
53.53
-0.62
-1.14%
Sanofi Adr stock is traded at $54.15, with a volume of 4.73M.
It is up +3.85% in the last 24 hours and up +12.30% over the past month.
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
See More
Previous Close:
$52.15
Open:
$53.82
24h Volume:
4.73M
Relative Volume:
2.01
Market Cap:
$136.54B
Revenue:
$53.04B
Net Income/Loss:
$4.93B
P/E Ratio:
27.44
EPS:
1.9736
Net Cash Flow:
$9.91B
1W Performance:
+4.19%
1M Performance:
+12.30%
6M Performance:
+4.78%
1Y Performance:
+7.78%
1-Day Range:
$53.70
$54.86
1-Week Range:
$52.14
$54.86
52-Week Range:
$45.22
$58.97
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
54.15 | 136.54B | 53.04B | 4.93B | 9.91B | 1.9736 |
|
LLY
Lilly Eli Co
|
823.23 | 778.66B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.34 | 379.90B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
152.87 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
175.59 | 310.55B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
Sanofi Reports Strong Q4 Sales Growth, Plans €5 Billion Buyback in 2025 - GuruFocus.com
Sanofi ADR (SNY) Recovers 15.33% From Low: Are We There Yet? - Stocks Register
Sanofi ADR earnings beat by $0.53, revenue fell short of estimates - Investing.com
Communiqué de presse : Croissance des ventes de 10,3% au T4. Objectif du BNPA des activités de 2024 dépassé. Fort rebond du BNPA des activités attendu en 2025 - GlobeNewswire Inc.
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Gsk Plc ADR (GSK-N) QuotePress Release - The Globe and Mail
3 Pharma Stocks To Buy As California Sounds The Alarm On Bird Flu Cases - Barchart
Communiqué de presse - GlobeNewswire Inc.
Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug - Investor's Business Daily
What Did We Find About Insider Trading At Sanofi ADR (NASDAQ: SNY)? - Stocks Register
Weekly Upgrades and Downgrades - InvestorPlace
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - MSN
Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Top-3 International Stocks Beating Their U.S. Peers for Dividend Earnings - TheStreet
Teva Pharmaceutical ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily
Novo Nordisk and AstraZeneca top 2025 drug picks for US investment bankread why - Proactive Investors USA
Why Sanofi (SNY) Is One of the Best ADR Stocks to Invest in? - Insider Monkey
12 Best ADR Stocks To Invest In According to Analysts - Insider Monkey
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):